Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Date
2020-07-10Author
Zost, Seth J.
Gilchuk, Pavlo
Chen, Rita E.
Case, James Brett
Reidy, Joseph X.
Trivette, Andrew
Nargi, Rachel S.
Sutton, Rachel E.
Suryadevara, Naveenchandra
Chen, Elaine C.
Binshtein, Elad
Shrihari, Swathi
Ostrowski, Mario
Chu, Helen Y.
Didier, Jonathan E.
MacRenaris, Keith W.
Jones, Taylor
Day, Samuel
Myers, Luke
Eun-Hyung Lee, F.
Nguyen, Doan C.
Sanz, Ignacio
Martinez, David R.
Rothlauf, Paul W.
Bloyet, Louis-Marie
Whelan, Sean P. J.
Baric, Ralph S.
Thackray, Larissa B.
Diamond, Michael S.
Carnahan, Robert H.
Crowe, James E.
Metadata
Show full item record
Documentos PDF
Summary in foreign language
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.
Link to resource
https://www.nature.com/articles/s41591-020-0998-x#article-infoCollections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.